Synairgen plc (AIM:SNG)

Market Cap	22.05M
Revenue (ttm)	n/a
Net Income (ttm)	-6.92M
Shares Out	1.10B
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	362,789
Average Volume	473,223
Open	2.060
Previous Close	2.180
Day's Range	2.000 - 2.350
52-Week Range	1.700 - 10.000
Beta	-2.14
RSI	42.64
Earnings Date	May 9, 2025

About Synairgen

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 36
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: SNG